The announcement comes during the worst outbreak of Ebola recorder with the virus killing close to 1,000 people in West Africa. The Ebola vaccine trial is waiting for approval from the U.S. Food and Drug Administrationg to Phase I testing in humans.
GlaxoSmithKline’s drug has already shown plenty of promise in its animal studies with primates. The clinical trial could begin as early as fall 2014.
Ebola has no proven cure or vaccine to prevent infection. The World Health Organisation has declared the outbreak an international health emergency.
GSK stock is flat Monday afternoon.
More Health News:
- Toothpaste Alert: Colgate Total Contains Cancer-Linked Triclosan
- Walmart Wants to Be Your Doctor: In-Store Clinics Open
- FDA Issues Tattoo Ink Warning